Discover
EHA Unplugged
EHA Unplugged
Author: European Hematology Association
Subscribed: 37Played: 1,541Subscribe
Share
© European Hematology Association
Description
Discover what's new and what's next in haematology / hematology. Leading experts insights into leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic lymphocytic leukaemia (CLL), stem cell transplantation, sickle cell disease, thalassemia, anemias, CAR T-cell therapy, immunotherapy and more. Unplug from your screen and enjoy the podcasts for and from haematologists / hematologists of the European Hematology Association (EHA).
205 Episodes
Reverse
How is blood regenerated after hematopoietic stem cell transplantation (HSCT), and what happens to the transplanted hematopoietic system over the long term? In this episode of EHA Unplugged, host Isabel Olivera speaks with Dr. Mirjam Belderbos of the Princess Máxima Center in the Netherlands about lifelong blood production, stem-cell aging, and the biology of clonal hematopoiesis. Together, they explore how transplantation reshapes clonal dynamics, why post-transplant clonal hematopoiesis can occur earlier and at higher levels than in the general aging population, and how both donor age and the transplant procedure may influence its development. Dr. Belderbos explains why these clones should be considered a distinct biological entity—and why their clinical consequences, including potential links to cytopenias, malignancy, and other late effects, remain uncertain. The discussion also highlights key questions for long-term follow-up: when should clinicians be concerned, and could intervention ever be appropriate? Tune in for an accessible conversation on an emerging area of hematology research with important implications for transplant survivors.Guests: Dr. Mirjam Belderbos Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands Host: Isabel Olivera-Martínez, PhD, Medical Writer for EHA Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe
Pediatric hematology training varies widely across Europe. In this podcast episode, Professors Andishe Attarbaschi and Josef Vormoor introduce the new EHA-SIOPe Pediatric Hematology #Syllabus, a shared framework for comprehensive, consistent training. They explain that more than 50 experts contributed to the development of the syllabus, which complements the adult curriculum while addressing pediatric-specific needs. Attarbaschi describes how the syllabus can help national societies adapt their own training pathways, while Vormoor highlights its modular structure, which allows it to be adapted to different national training systems. This conversation shows why this syllabus can sustain the foundation for better, more consistent and comprehensive pediatric hematology training across Europe. The syllabus is open access on the EHA and SIOPe websites: EHA-SIOPe Pediatric Extended Syllabus - The European Hematology Association (EHA).Guests: Prof. Josef Vormoor Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands Prof. Andishe Attarbaschi St. Anna Children’s Hospital, Vienna, Austria Host: Isabel Olivera-Martínez, PhD, Medical Writer for EHA Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe
The patient voice is no longer optional. Samantha Nier, Chair of the Patient Advocacy Committee (PAC) at EHA and a leader within the Acute Leukemia Advocates Network (ALAN) explains why clinical trials change for the better when patients are involved from the start. She highlights the importance of involving patients in clinical trial design, informed consent, and research protocols so that care decisions reflect not only scientific goals, but also real-life patient experience, quality of life, and treatment burden. Samantha shows also how patient organizations contribute to many EHA initiatives, helping to shape guidelines, scientific congress sessions and European-level projects. A thoughtful discussion about advocacy, inclusion, and the power of listening to the people most affected by disease. Guests: Samantha Nier Affiliation: Chair of EHA's Patient Advocate Committee & Network Director of Acute Leukemia Advocates Network Host: Isabel Olivera-Martínez, PhD, Medical Writer for EHA Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe
Follicular lymphoma (FL) is entering a new era: from decades of chemotherapy to increasingly effective, less toxic biological and immunotherapy-based approaches. In this podcast episode of EHA Unplugged, hear directly from the authors of the latest EHA guidelines on FL: Prof Marco Ladetto (University of Eastern Piedmont, Italy) and Prof Martin Dreyling (LMU Munich, Germany). They start by discussing the importance of histological confirmation and grading, the role—and current limits—of molecular profiling, and how FLIPI-based risk assessment can inform treatment intensity. The conversation covers active surveillance for asymptomatic disease, first-line immunochemotherapy, chemo-free options such as rituximab–lenalidomide and novel antibody-based combinations, and sequencing CAR T-cell therapy and bispecific antibodies in later relapses. The experts also address survivorship, long-term toxicity, patient preferences, and the strategic need to preserve effective options across a potentially decades-long disease course. Tune in for practical, evidence-based insights to support individualised follicular lymphoma care. Guests: Prof Marco Ladetto University of Eastern Piedmont and SCDU Ematologia, Alessandria, ItalyProf Martin Dreyling Ludwig-Maximilian-University, Munich, Germany Host: Isabel Olivera-Martínez, PhD, Medical Writer for EHA Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe
Explore the latest EHA guidelines on chronic lymphocytic leukemia (CLL) and Richter transformation with key guideline authors Prof Barbara Eichhorst, hematologist at University Hospital Cologne (Germany), and Prof Paolo Ghia, Director of the CLL Program at Università Vita-Salute San Raffaele (Milan, Italy). For the first time, the guidelines no longer recommend chemoimmunotherapy when targeted options are available, based on two key advances: the approval of acalabrutinib plus venetoclax with or without obinutuzumab for frontline CLL, and the approval of pirtobrutinib, a non-covalent BTK inhibitor, for relapsed/refractory disease—particularly after prior covalent BTK inhibitor treatment. The guests also make clear that patient selection matters, including TP53 status, IGHV status, comorbidities, co-medications, safety profile, and patient preferences. Further, the experts highlight a landmark change in how the recommendations were developed: for the first time, patients and patient advocates participated as authors, bringing a patient-centred perspective to treatment decisions, active surveillance, and supportive care. Tune in for practical insights into personalized CLL management, fixed-duration targeted therapy, treatment sequencing, and the challenges of Richter transformation.Guests: Prof Barbara Eichhorst University of Cologne, Cologne, Germany Prof Paolo Ghia Università Vita-Salute San Raffaele, Milano, Italy Host: Isabel Olivera-Martínez, PhD, Medical Writer for EHA Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe








